Select Language
FOLR1
FOLR1 Overview
| English Name | Folate receptor alpha | Approved Drugs | 3 |
| Drugs in Clinical Trials | 20 | Target Synonym | FRalpha，KB cells FBP，Adult folate-binding protein，Folate receptor 1，Folate receptor alpha，FR-alpha，FOLR1，Ovarian Tumor-Associated Antigen MOv18，Folate Receptor 1 (Adult)，Folate Receptor， Adult，FOLR，FBP，Folate Binding Protein，FRα |
| Highest Development Stage | Approved | ||
| English Name | Folate receptor alpha |
| Target Synonym | FRalpha，KB cells FBP，Adult folate-binding protein，Folate receptor 1，Folate receptor alpha，FR-alpha，FOLR1，Ovarian Tumor-Associated Antigen MOv18，Folate Receptor 1 (Adult)，Folate Receptor， Adult，FOLR，FBP，Folate Binding Protein，FRα |
| Approved Drugs | 3 |
| Drugs in Clinical Trials | 20 |
| Highest Development Stage | Approved |
FOLR1 Product List
- Product Category
Protein (22)Cell (1)Antibody (1)
- Product Status
Launched (26)
- Species
Mouse (6)Cynomolgus / Rhesus macaque (4)Human (13)Rabbit (1)
- Tag
His Tag (10)His Tag & Avi Tag (6)Fc Tag (4)Fc Tag & Avi Tag (2)- (4)
- Conjugate
Unconjugated (11)Biotin-labeled (8)FITC Labeled (1)PE Labeled (2)APC Labeled (1)- (3)
Add to Cart
Total: 24
- 1
- 2
- 3
FOLR1 Background
Folate Receptor 1 (FOLR1) is also known as Folate receptor alpha, Folate Binding Protein (FBP), FOLR, and is a member of the folate receptor (FOLR) family. Members of this gene family have a high affinity for folic acid and for several reduced folic acid derivatives, and mediate delivery of 5-methyltetrahydrofolate to the interior of cells. Mature FOLR1 is an N-glycosylated protein that is anchored to the cell surface by a GPI linkage. FOLR1 is predominantly expressed on epithelial cells and is dramatically upregulated on many carcinomas. FOLR1 is internalized to the endosomal system where it dissociates from its ligand before recycling to the cell surface. A soluble form of FOLR1 can be proteolytically shed from the cell surface into the serum and breast milk. Defects in FOLR1 are the cause of neurodegeneration due to cerebral folate transport deficiency (NCFTD). NCFTD is an autosomal recessive disorder resulting from brain-specific folate deficiency early in life.
FOLR1 Synonyms
FOLR-1,FBP,FOLR,FRα
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| FRα BsAb - 01 | PCC | Bispecific | Humanized Mouse,Nanobody | Solid Tumor | Ovarian cancer,Non-small cell lung cancer |
Project Cooperation
| Project Name | Drug Type | Therapeutic Area | Indication | Stage | Rights Area |
|---|---|---|---|---|---|
| FRα BsAb-ADC | Bispecific antibody | Oncology/Cancer | Ovarian cancer | Preclinical | Global |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| CBP-1008 | CBP-1008 | Phase 3 Clinical | Coherent Biopharma Suzhou Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms | Details |
| Arfolitixorin | ISO-901; 6R-MTHF | Phase 3 Clinical | Isofol Medical Ab | Rectal Neoplasms; Colonic Neoplasms; Osteosarcoma; Colorectal Neoplasms | Details |
| Luveltamab tazevibulin | STRO-002 | Phase 3 Clinical | Sutro Biopharma Inc | Solid tumours; Ovarian Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung | Details |
| Rinatabart Sesutecan | GEN1184; GEN-1184; PRO-1184 | Phase 3 Clinical | ProfoundBio (Suzhou) Co Ltd | Ovarian Neoplasms; Solid tumours; Cystadenocarcinoma, Serous; Triple Negative Breast Neoplasms; Mesothelioma; Breast Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Farletuzumab | MORAb-003 | Phase 2 Clinical | Morphotek Inc | Ovarian Neoplasms; Solid tumours; Adenocarcinoma of Lung; Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
| AZD5335 | AZD5335; AZD-5335 | Phase 2 Clinical | Astrazeneca Plc | Ovarian Neoplasms; Solid tumours; Adenocarcinoma of Lung | Details |
| Farletuzumab ecteribulin | MORAb-202 | Phase 2 Clinical | Morphotek Inc, Bristol-Myers Squibb Company, Eisai Co Ltd | Solid tumours; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| BAT-8006 | BAT8006; BAT-8006 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
| 4S-CAR-FRa | 4S-CAR-FRa | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms | Details |
| CBP-1019 | CBP-1019 | Phase 2 Clinical | Coherent Biopharma Suzhou Co Ltd | Solid tumours; Ovarian Neoplasms; Esophageal Neoplasms; Thoracic Neoplasms; Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Urogenital Neoplasms; Lung Neoplasms; Gastrointestinal Neoplasms | Details |
| Noscapine-folate conjugate | Phase 1 Clinical | Emory University | Hematologic Neoplasms; Inflammation | Details | |
| MOv-18 IgE | MOv-18 IgE; MOv18; MOv-18 | Phase 1 Clinical | King'S College London, Cancer Research UK | Ovarian Neoplasms; Neoplasms | Details |
| ITIL-306 | ITIL-306 | Phase 1 Clinical | Instil Bio Inc | Solid tumours; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Genital Neoplasms, Female; Carcinoma, Non-Small-Cell Lung | Details |
| IMGN-151 | IMGN-151 | Phase 1 Clinical | Immunogen Inc | Ovarian Neoplasms; Cystadenocarcinoma, Serous; Breast Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms | Details |
| FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy(Fred Hutchinson Cancer Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Leukemia, Myeloid, Acute | Details | |
| LY-4170156 | LY4170156; LY-4170156 | Phase 1 Clinical | Eli Lilly And Company, Loxo Oncology Inc | Ovarian Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| ZW-191 | ZW-191 | Phase 1 Clinical | Zymeworks Inc | Solid tumours; Ovarian Neoplasms; Genital Neoplasms, Female; Carcinoma, Non-Small-Cell Lung | Details |
| AMT-151 | AMT-151 | Phase 1 Clinical | Multitude Therapeutics Inc | Ovarian Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Adenocarcinoma of Lung; Neoplasms; Mesothelioma; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Endometrioid | Details |
| UB-TT170 | UB-TT-170; UB_TT170; UB_TT-170; UB-TT170 | Phase 1 Clinical | Umoja BioPharma Inc | Osteosarcoma | Details |
| CBP-1018 | CBP-1018 | Phase 1 Clinical | Coherent Biopharma Suzhou Co Ltd | Solid tumours; Carcinoma, Renal Cell; Prostatic Neoplasms; Lung Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pafolacianine Sodium | Pteroyl-L-Tyr-S0456; OTL-38; EC-17; OTL-0038 | Approved | On Target Laboratories Inc | Cytalux | United States | Ovarian Neoplasms | On Target Laboratories Inc | 2021-11-29 | Ovarian Neoplasms; Inflammatory Bowel Diseases; Neoplasms; Arthritis, Rheumatoid; Breast Neoplasms; Pituitary Neoplasms; Peritoneal Neoplasms; Lung Neoplasms; Gastrointestinal Neoplasms | Details |
| Mirvetuximab soravtansine | M9346-Asulfo-SPDB-DM4; IMGN-853; M9346A-sSPDB-DM4; TAK-853 | Approved | Immunogen Inc | Elahere, 爱拉赫 | United States | Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial | Immunogen Inc | 2022-11-14 | Ovarian Neoplasms; Solid tumours; Cystadenoma, Serous; Fallopian Tube Diseases; Carcinoma, Ovarian Epithelial; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinosarcoma; Uterine Neoplasms; Peritoneal Diseases | Details |
| Folinic Acid | FTHF | Approved | Autism Spectrum Disorder; Anemia; Down Syndrome; Rectal Neoplasms; Diarrhea; Colorectal Neoplasms; Vitamin B 12 Deficiency | Details |
Product Reviews
W***I2025-11-07
0People LikeThis FOLR1 protein performed well in the ELISA binding activity detection method, with good repeatability, high quality and cost-effectiveness, and experimental results meet expectations.- p***g2025-01-23 0People LikeAs expected, this was a high quality product. I have purchased multiple products from Acro to develop assays in the past. As usual, purity and quantity was confirmed by our in-house quality control group. We are using this in conjunction with #FO1-H82E2 Biotinylated Human FOLR1 Protein, His Avitag. The product was used successfully in an immunization campaign and will also be used for other in-house assays in the future.
- D***m2022-10-26 0People LikeWe had to order human folate receptor protein for 100 micrograms unit type for one of our sensitive studies. It was crucial that the product work as intended. We received the product in a timely manner, and the product work as intended for one of our studies. As an employee working at a lab, I thank you for all the scientists working hard to make great products!
Load More
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland